Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NuGen Medical Devices Inc ( (TSE:NGMD) ) has shared an update.
NuGen Medical Devices Inc. has announced that its EziAutoJector® product line has been approved for inclusion in the NHS Drug Tariff in the UK. This approval allows individuals with diabetes to receive the needle-free insulin delivery device at no cost as part of NHS-funded care, aligning with NICE guidelines for personalized patient choice. The approval is expected to enhance NuGen’s market positioning by increasing product accessibility and reducing environmental impact through decreased biohazardous waste, supporting NHS environmental and cost-efficiency goals.
More about NuGen Medical Devices Inc
NuGen Medical Devices Inc. is a leader in needle-free subcutaneous drug-delivery technology. The company develops next-generation needle-free devices, with its flagship InsuJet™ system approved in 42 countries, aiming to improve the lives of millions of people with diabetes worldwide.
Average Trading Volume: 122,878
Technical Sentiment Signal: Sell
Current Market Cap: C$10.22M
For an in-depth examination of NGMD stock, go to TipRanks’ Overview page.